Skip to main content
main-content

Pediatric rheumatology

Juvenile idiopathic arthritis

14-06-2019 | Juvenile idiopathic arthritis | EULAR 2019 | News

Similar JIA outcomes with switch to second TNF inhibitor vs alternative biologic

Juvenile idiopathic arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapy have similar outcomes regardless of whether they switch to a second agent from the same class or an alternative biologic, research suggests.

ACR/National Arthritis Foundation guidelines for managing JIA released

The ACR and the National Arthritis Foundation have published two guidelines on juvenile idiopathic arthritis, one providing recommendations for the treatment of polyarthritis, sacroiliitis, and enthesitis, and the other focusing on detecting and treating uveitis.

07-05-2019 | Juvenile idiopathic arthritis | Highlight | News

ACR/National Arthritis Foundation guidelines for managing JIA released

The ACR and the National Arthritis Foundation have published two guidelines on juvenile idiopathic arthritis, one providing recommendations for the treatment of polyarthritis, sacroiliitis, and enthesitis, and the other focusing on detecting and treating uveitis.

29-04-2019 | Etanercept biosimilar | News

FDA approves etanercept biosimilar

Click through for more information on this announcement

18-04-2019 | Juvenile idiopathic arthritis | View from the clinic | Article

Enabling pediatric patients to make informed treatment choices

Editorial board member Sangeeta Sule reflects on the challenges of enabling pediatric patients to make informed decisions about their own healthcare.

Enabling pediatric patients to make informed treatment choices

Editorial board member Sangeeta Sule reflects on the challenges of enabling pediatric patients to make informed decisions about their own healthcare.

27-03-2019 | Juvenile idiopathic arthritis | Editorial | Article

Temporomandibular joint involvement in juvenile idiopathic arthritis: Diagnosis and management

The authors provide an overview of temporomandibular joint involvement in children with juvenile idiopathic arthritis, including imaging methods for diagnosis, clinical examination recommendations, and treatment options.

Temporomandibular joint involvement in juvenile idiopathic arthritis: Diagnosis and management

The authors provide an overview of temporomandibular joint involvement in children with juvenile idiopathic arthritis, including imaging methods for diagnosis, clinical examination recommendations, and treatment options.

Enhancing clinical assessment with ultrasonography in juvenile idiopathic arthritis

Johannes Roth outlines the rationale behind the use of musculoskeletal ultrasonography in children with juvenile idiopathic arthritis, including enhancement of clinical assessment as part of a treat-to-target approach.

18-03-2019 | Juvenile idiopathic arthritis | Editorial | Article

Enhancing clinical assessment with ultrasonography in juvenile idiopathic arthritis

Johannes Roth outlines the rationale behind the use of musculoskeletal ultrasonography in children with juvenile idiopathic arthritis, including enhancement of clinical assessment as part of a treat-to-target approach.

The microbiota in juvenile idiopathic arthritis: What’s wrong, and what can we do?

In this editorial, Matthew Stoll explores the role of the microbiota in the pathogenesis of juvenile idiopathic arthritis, as well as current research into therapeutic alterations of the microbiome.

01-03-2019 | Juvenile idiopathic arthritis | Editorial | Article

The microbiota in juvenile idiopathic arthritis: What’s wrong, and what can we do?

In this editorial, Matthew Stoll explores the role of the microbiota in the pathogenesis of juvenile idiopathic arthritis, as well as current research into therapeutic alterations of the microbiome.

28-02-2019 | Juvenile idiopathic arthritis | News

Substantial proportion of patients with JIA have ongoing disease as adults

Almost half of patients with juvenile idiopathic arthritis have ongoing active disease during early adulthood, with the burden particularly high among those with enthesitis-related arthritis, researchers report.

22-02-2019 | Adalimumab biosimilar | News

EMA gives nod to two adalimumab biosimilars

The Committee for Medicinal Products for Human Use has recommended two new adalimumab biosimilars for approval in Europe.

11-01-2019 | Juvenile idiopathic arthritis | News

Predictors of outcomes identified in JIA-associated uveitis

Demographic factors, measures of disease activity, and the type of treatment used are associated with 2-year outcomes among patients with juvenile idiopathic arthritis-associated uveitis, according to findings from the ICON-JIA study.

Growing up right: Transitioning from pediatric to adult rheumatology care

Sangeeta Sule outlines the challenges of transitioning from pediatric to adult rheumatology care, highlights key resources to support families and healthcare providers, and provides tips on managing the transition process.

26-11-2018 | Juvenile idiopathic arthritis | News

Disease subtype, treatment choice may impact infection risk in JIA patients

Among biologic-treated patients with juvenile idiopathic arthritis, infection risk may differ according to disease subtype and the biologic agent used, researchers report.

09-11-2018 | Juvenile idiopathic arthritis | News

Activity tracking ‘feasible’ for adolescents with JIA

Findings from a pilot study indicate that activity tracking using a wrist-worn device is a feasible approach for promoting physical activity in adolescent patients with juvenile idiopathic arthritis

Vaccination in children and adolescents with rheumatic conditions

In this editorial, the authors discuss the risks of live vaccination in children taking antirheumatic medications and how to manage these, as well as how health authorities can address decreasing vaccination coverage of the general public.

18-10-2018 | Infection | Editorial | Article

Vaccination in children and adolescents with rheumatic conditions

In this editorial, the authors discuss the risks of live vaccination in children taking antirheumatic medications and how to manage these, as well as how health authorities can address decreasing vaccination coverage of the general public.

Image Credits